Clinical Data ECO 2026: gut hormone signals differ in T1D with obesity Pharmaceutical TechnologyAt ECO 2026, researchers presented a study assessing fasting PYY, ghrelin and GIP levels in T1D patients, with or without obesity.Metabolic & GLP-1Read full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology At ECO 2026, researchers presented a study assessing fasting PYY, ghrelin and GIP levels in T1D patients, with or without obesity. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Zydus to acquire Assertio in $166m dealNext: Regulatory round-up: A month of key FDA approvals for cancer drugs Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
